BURLINGTON, Mass., Jan. 6, 2011 (GLOBE NEWSWIRE) -- Palomar Medical Technologies, Inc. (Nasdaq:PMTI), a leading researcher and developer of light-based systems for cosmetic treatments, will host an analyst and investor meeting to discuss its launch plans for the first FDA-cleared, at-home laser clinically proven to reduce fine lines and wrinkles around the eyes - the PaloVia™ Skin Renewing Laser™. The meeting will be held today from 10AM to 12PM in New York City at the Nasdaq MarketSite, 4 Times Square, second floor Press Conference Room. Presenters from Palomar will be Joseph Caruso, Chief Executive Officer; Paul Weiner, Chief Financial Officer; Nancy Teumer, Global Marketing Director Consumer Products; David Montgomery, Consumer Products Sales Director; and Richard Bankowski, Field Clinical Director and QVC Spokesperson. Also presenting will be Palomar's PaloVia Expert Panel member, Dr. Robert Weiss, Director, Maryland Laser, Skin & Vein Institute. Attendees are asked to arrive early to allow adequate time for security checks. For analysts and investors that are not able to attend the PaloVia launch meeting in New York City, the meeting will also be accessible via webcast in the About Palomar/Investors section of Palomar's website at palomarmedical.com.
About Palomar Medical Technologies, Inc.: Palomar Medical Technologies (Nasdaq:PMTI) designs, produces and sells the most advanced cosmetic lasers and intense pulsed light (IPL) systems to dramatically improve the appearance of women's and men's skin. For over 15 years, Palomar has pioneered the science of using lasers and light to improve appearances. As the industry's technology leader, Palomar has invested in creating cosmetic laser and IPL systems that put real value in the hands of physicians and other professionals to benefit consumers. Thousands of physicians worldwide trust and depend on Palomar technology to not only introduce new aesthetic treatments such as advanced laser hair removal, laser liposuction, skin resurfacing, acne, laser treatments for scars, wrinkle treatment, stretch marks (striae), and photofacials for pigmented and vascular lesions, but to also make them robust, faster, more powerful, and more comfortable for those being treated. In June 2009, Palomar became the first company to receive a 510(k) over-the-counter ("OTC") clearance from the FDA for a new, patented, home-use, laser device for the treatment of fine lines and wrinkles around the eyes (periorbital wrinkles). OTC clearance allows these products to be marketed and sold directly to consumers without a prescription.
For more information on Palomar and its professional products, visit the company's website at palomarmedical.com. To continue receiving the most up-to-date information and latest news on Palomar as it happens, sign up to receive automatic e-mail alerts by going to the About Palomar/Investors section of the website.
For more information on PaloVia, visit the PaloVia website at palovia.com.
CONTACT: Palomar Medical Technologies, Inc. Investor/Financial Contact: Kerry McAnistan, Investor Relations Assistant 781-993-2411 ir@palomarmedical.com Bratskeir & Company Consumer Media Contact: Lauren Glicken O'Leary lgoleary@bratskeir.com Rebecca Levitt rlevitt@bratskeir.com 212-679-2233